| This is the
talk page for discussing improvements to the
Olaparib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Olaparib.
|
Does it inhibit just PARP1 or other PARP enzymes ? Rod57 ( talk) 11:43, 22 October 2009 (UTC)
The Journal of the National Cancer Institute gave olaparib as an example of exaggerated coverage in the news media. Promoting Healthy Skepticism In The News: Helping Journalists Get It Right
Try to keep out some of the more hysterical claims. -- Nbauman ( talk) 01:56, 23 November 2009 (UTC)
An FDA news release announces:
- FDA approves Lynparza to treat advanced ovarian cancer
- First LDT companion diagnostic test also approved to identify appropriate patients
Hope this is useful. -- Hordaland ( talk) 02:08, 20 December 2014 (UTC)
It would be helpful to get some statistical estimates of how many people have taken this medication. That would help me, as a consumer, evaluate its effectiveness and safety. I think it's a fairly rare medication, but I'm not sure. — Preceding unsigned comment added by Skysong263 ( talk • contribs) 15:16, 8 May 2018 (UTC)
Reference #6 (to: http://www.emea.europa.eu/pdfs/human/comp/opinion/51078707en.pdf ) referes to non-existent target.
| This is the
talk page for discussing improvements to the
Olaparib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
|
| This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
|
| Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Olaparib.
|
Does it inhibit just PARP1 or other PARP enzymes ? Rod57 ( talk) 11:43, 22 October 2009 (UTC)
The Journal of the National Cancer Institute gave olaparib as an example of exaggerated coverage in the news media. Promoting Healthy Skepticism In The News: Helping Journalists Get It Right
Try to keep out some of the more hysterical claims. -- Nbauman ( talk) 01:56, 23 November 2009 (UTC)
An FDA news release announces:
- FDA approves Lynparza to treat advanced ovarian cancer
- First LDT companion diagnostic test also approved to identify appropriate patients
Hope this is useful. -- Hordaland ( talk) 02:08, 20 December 2014 (UTC)
It would be helpful to get some statistical estimates of how many people have taken this medication. That would help me, as a consumer, evaluate its effectiveness and safety. I think it's a fairly rare medication, but I'm not sure. — Preceding unsigned comment added by Skysong263 ( talk • contribs) 15:16, 8 May 2018 (UTC)
Reference #6 (to: http://www.emea.europa.eu/pdfs/human/comp/opinion/51078707en.pdf ) referes to non-existent target.